A company with its origins in scientific excellence



  • Formycon appoints development und production expert Thomas Siklosi to the Advisory Board
  • Biosimilar candidate FYB201 shows efficacy comparable to the reference product in clinical phase III
  • Formycon ranks 7th in the Financial Times list of Europe’s 1000 strongest-growing companies


  • Formycon and Aristo Pharma establish joint venture for FYB202
  • Focus: Formycon again awarded as growth champion
  • Pipeline news: FYB202 is a biosimilar candidate for Stelara®
  • Formycon changes in new SME stock exchange segment “Scale”


  • Focus magazine lists Formycon as growth champion 2017
  • German Stifterverband awards Formycon for innovative strength
  • Santo Holding (Deutschland) GmbH tranfers global commercialization rights for FYB201 to Bioeq IP AG
  • Dr. Carsten Brockmeyer again honored as one of the most influential people in medicines industry
  • Expansion of product pipeline with fourth biosimilar candidate
  • Details on FYB203: Formycon develops biosimilar for Eylea® (aflibercept)
  • Appointment of biotech expert Professor Johannes Buchner to Advisory Board
  • Enrollment of first patient in pivotal phase III study with Lucentis® biosimilar (FYB201)


  • Formycon and bioeq initiate pivotal phase III clinical trial with Lucentis® biosimilar (FYB201)
  • Out-licensing of second biosimilar to Santo Holding
  • Medicine Maker: Dr. Carsten Brockmeyer under Top 20 in medicines industry
  • Capital increase of EUR 11.1 million
  • Successful GMP inspection


  • Development of third product begins


  • Successful completion of capital increase totaling EUR 17.5 million
  • Start of development of first and second product
  • Out-licensing of first biosimilar from Formycon product pipeline


  • Renaming to Formycon AG
  • Leadership in the development of high-quality biopharmaceutical follow-up-products


  • Scil Technology GmbH licenses its flagship project to Sanofi


  • Scil Technology GmbH establishes a dedicated research and services unit under the name “Formycon”


  • Scil Technology GmbH licenses project portfolio to Medtronic


  • Alongside its own R&D projects, Scil Technology GmbH wins its first service-provider contracts, conducting its first biosimilar development projects on behalf of clients


  • Analytical laboratory receives GMP certification


  • Former executives of Boehringer Mannheim found Scil Technology GmbH